Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -124.99% | 49.11% | 330.74% | 69.83% | -699.19% |
| Total Depreciation and Amortization | -9.25% | 15.16% | -21.62% | 47.05% | 8.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 406.28% | 457.32% | -111.49% | -1.84% | 462.88% |
| Change in Net Operating Assets | -80.38% | -30.51% | 202.56% | -188.07% | 216.87% |
| Cash from Operations | -28.96% | 16.99% | 239.00% | -49.59% | 472.40% |
| Capital Expenditure | 81.72% | -560.33% | -21.67% | 33.56% | -72.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | 97.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.05% | 439.36% | -283.18% | -64.42% | -80.16% |
| Cash from Investing | -146.52% | 329.24% | -222.11% | 98.61% | -427.06% |
| Total Debt Issued | -- | -- | -- | -- | 5,947.21% |
| Total Debt Repaid | -206.27% | 58.00% | -495.71% | 91.03% | -1,963.55% |
| Issuance of Common Stock | 479.46% | -15.79% | 5.56% | -65.29% | 218.42% |
| Repurchase of Common Stock | 87.40% | -174.48% | -- | -- | 99.82% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -197.84% | 78.01% | -188.00% | 66.48% | -437.43% |
| Cash from Financing | -87.08% | 38.61% | -481.81% | -111.68% | 1,221.65% |
| Foreign Exchange rate Adjustments | -6.27% | 289.34% | -174.75% | 129.63% | -547.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.97% | 683.71% | -232.06% | 111.88% | -211.14% |